NDC product
Sodium Phosphates
NDC 63323-881 · Fresenius Kabi USA, LLC
Key facts
| Product NDC | 63323-881 |
|---|---|
| Proprietary name | Sodium Phosphates |
| Nonproprietary name | sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous |
| Substances | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Fresenius Kabi USA, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA209997 |
| Pharmacologic classes | Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Laxative [EPC] |
| Marketing start | Mar 30, 2022 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: